Loading, Please Wait...
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the Second Annual 2019 Hemophilia Drug Development (HDD) Summit being held from August 20-22, 2019 in Boston.
Dr. Howard Levy, chief medical officer of Catalyst, will discuss previously presented preclinical and clinical data of the Company’s two subcutaneous factors for prophylaxis, Factor VIIa, marzeptacog alfa (activated) (MarzAA) and Factor IX, dalcinonacog alfa (DalcA), comparing and contrasting their clinical use due to differences in their pharmacokinetic properties. Dr. Grant Blouse, vice president, translational research at Catalyst, will lead a workshop on understanding the immunogenicity of coagulation factor replacement products.
|Oral presentation details|
|Presentation Title:||A Tale of Two Subcutaneous Coagulation Factors|
|Presenter:||Howard Levy, M.B.B.Ch., Ph.D., M.M.M.|
|Session:||Advancing Novel Prophylaxis that Improves Quality of Life for Patients|
|Date/Time:||Wednesday, Aug. 21 from 12:30 – 1 p.m. EDT|
|Presentation Title:||Understanding Immunogenicity in Next Generation Factor Replacement Prophylaxis|
|Presenter:||Grant Blouse, Ph.D.|
|Date/Time:||Tuesday, Aug. 20 from 9:00 a.m. – 12:00 p.m. EDT|
A copy of the presentation materials can be accessed on the Events and Presentations section of the Catalyst website once the presentations conclude.
About Catalyst Biosciences
Catalyst is a clinical-stage biopharmaceutical company focused on developing novel treatments for hemophilia and other rare bleeding disorders using its potent, subcutaneous (SQ) coagulation factors that promote blood clotting. The Company’s engineered coagulation factors are designed to overcome the significant limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes using SQ dosing. For more information, please visit www.catalystbiosciences.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential uses and benefits of MarzAA and DalcA to treat patients with hemophilia, clinical trial results and immunogenicity risks. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of MarzAA or DalcA, including the generation of antibodies, which has been observed in patients treated with DalcA, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, competition and other factors that affect our ability to establish collaborations on commercially reasonable terms and other risks described in the “Risk Factors” section of the Company’s annual report filed with the Securities and Exchange Commission on March 8, 2019, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
Fletcher Payne, CFO
Catalyst Biosciences, Inc.
Josephine Belluardo, Ph.D.
LifeSci Public Relations